ripekg:evaluation/RIPEA3A616563C128D80E |
prov:wasInformedBy |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
rdf:type |
rdfs:Resource |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
rdf:type |
owl:Thing |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
rdf:type |
ripe:EvidenceAggregationEvidence aggregation |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
rdf:type |
tido:Activity |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
prov:startedAtTime |
2026-04-05T15:49:58.526068Z |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI 1.0.0 |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA3A616563C128D80E |
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
ripekg:registry-evidence/RIPEA3A616563C128D80E |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
ripekg:retraction-notice/22386Bioinformatic Analysis of Codon Usage and Phylogenetic Relationships in Different Genotypes of the Hepatitis C Virus |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
ripekg:retraction-notice/22387Bioinformatic Analysis of Codon Usage and Phylogenetic Relationships in Different Genotypes of the Hepatitis C Virus |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |
ripekg:study-design-evidence/RIPEA3A616563C128D80E |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA3A616563C128D80E |